WASHINGTON — Foreign governments and corporations could profit from American academic institutions’ failure to safeguard taxpayer-funded biomedical research, according to a set of new reports from a federal watchdog.
Even though this is a US centric item, its points about institution conflicts of interest and overseas funding are very relevant to Australasia. It also makes some good comments about pharmacology research.
“The concern, generally speaking, is whether financial interests threaten or distort the use of NIH funds for their intended research purpose or the results of that scientific research,” Erin Bliss, an assistant HHS inspector general, said in an interview. “There are also concerns around the diversion of intellectual property, which could be an economic or a national security risk, and the potential for distortion or inappropriate influence of funding decisions.”